Hypercalcemia of Malignancy Management

Algorithm Steps

1. ▶

   Start

   Elevated Calcium in Cancer Patient

   Corrected Ca >10.5 mg/dL or ionized Ca >5.3 mg/dL

   1. ◆

      Decision

      Assess Severity

      Corrected calcium level determines urgency

      • MILD: 10.5-11.9 mg/dL - Often asymptomatic
      • MODERATE: 12-13.9 mg/dL - Symptoms common
      • SEVERE: ≥14 mg/dL - Medical emergency
      • Corrected Ca = Measured Ca + 0.8 × (4 - Albumin)
      1. ●

         Action

         Mild Hypercalcemia (10.5-11.9)

         Often can be managed as outpatient

         • Encourage oral hydration 2-3L/day
         • Avoid thiazides, lithium, vitamin D excess
         • Treat underlying malignancy
         • May not require specific therapy if asymptomatic
         • Recheck calcium in 1-2 weeks
         1. ✓

            Outcome

            Hypercalcemia Controlled

            Continue cancer treatment and monitoring

      2. ●

         Action

         Moderate-Severe (≥12 mg/dL)

         Requires active treatment

         • Symptoms: confusion, polyuria, constipation, nausea
         • Severe: lethargy, coma, arrhythmias
         • Admit for IV therapy
         1. ●

            Action

            Aggressive IV Fluid Resuscitation

            First-line treatment for all symptomatic HCM

            • Normal saline 200-500 mL/hr initially
            • Target urine output 100-150 mL/hr
            • Most patients are 3-6L volume depleted
            • Adjust rate based on cardiac/renal status
            • Monitor for fluid overload in elderly/CHF
            1. ◆

               Decision

               Severe or Life-Threatening?

               Ca ≥14 or severe symptoms

               • Altered mental status
               • Cardiac arrhythmias (shortened QT)
               • Seizures
               • Renal failure
               1. ●

                  Action

                  Add Calcitonin (Severe Cases)

                  Rapid onset but tachyphylaxis in 48h

                  • Calcitonin-salmon 4 IU/kg IM or SC q12h
                  • Onset: 4-6 hours (fastest option)
                  • Duration: 48-72h then tachyphylaxis
                  • Use as bridge while waiting for bisphosphonate
                  • Modest effect: lowers Ca by 1-2 mg/dL
                  1. ◆

                     Decision

                     Choose Antiresorptive Agent

                     Denosumab vs IV Bisphosphonate

                     • Both are first-line (strong recommendation)
                     • Denosumab may be preferred (conditional)
                     • Consider renal function and prior response
                     1. ●

                        Action

                        Denosumab 120 mg SC

                        Preferred in renal impairment

                        • Single dose 120mg SC
                        • Onset: 2-4 days
                        • No renal dose adjustment needed
                        • Risk of severe hypocalcemia - monitor closely
                        • Requires ongoing dosing to prevent rebound
                        • May repeat weekly if needed for refractory HCM
                        1. ●

                           Action

                           Monitor Response

                           Check calcium q12-24h initially

                           • Calcium should start falling within 24-48h
                           • Normocalcemia typically by day 4-7
                           • Monitor for hypocalcemia after treatment
                           • Continue hydration until calcium normalized
                           1. ◆

                              Decision

                              Calcium Normalized?

                              Assess response at 48-72 hours

                              1. ●

                                 Action

                                 Refractory HCM Management

                                 If no response to initial therapy

                                 • Switch class: BP → Denosumab or vice versa
                                 • Add glucocorticoids (if lymphoma/myeloma)
                                 • Consider dialysis if life-threatening
                                 • Cinacalcet (off-label) for parathyroid carcinoma
                                 • Treat underlying malignancy urgently
                              2. ●

                                 Action

                                 Maintenance & Prevention

                                 Prevent recurrence

                                 • Treat underlying cancer
                                 • Monthly zoledronic acid or denosumab
                                 • Calcium and vitamin D supplementation (careful dosing)
                                 • Monitor calcium monthly
                                 • Educate on symptoms of recurrence
                     2. ●

                        Action

                        IV Bisphosphonate

                        Zoledronic acid or pamidronate

                        • ZOLEDRONIC ACID: 4mg IV over 15 min
                        • PAMIDRONATE: 60-90mg IV over 2-4h
                        • Onset: 2-4 days, peak effect 4-7 days
                        • Reduce dose if CrCl <60 mL/min
                        • AVOID if CrCl <30 mL/min
                        • Duration: 2-4 weeks, can repeat
                        1. ⚠

                           Warning

                           ⚠️ Renal Impairment Considerations

                           Bisphosphonates can worsen renal function

                           • Ensure adequate hydration BEFORE bisphosphonate
                           • Reduce zoledronic acid dose for CrCl 30-60
                           • Use denosumab if CrCl <30
                           • Monitor creatinine 48-72h after infusion